Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: Application to clinical trial data on chronic lymphocytic leukaemia

Statistics in Medicine

Volumn 26, Issue 30, 2007, Pages 5411-5421

  Deslandes, Emmanuelle ^a,b,c   Chevret, Sylvie ^a,b,c  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Chronic lymphoctic leukaemia; Joint models; Mixed models; Multistate models; Non ignorable dropout; Surrogate marker

Indexed keywords

CHLORAMBUCIL; PREDNISONE;

ADULT; AGED; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAZARD RATIO; HEALTH STATISTICS; HUMAN; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; SURVIVAL RATE; WATCHFUL WAITING;

BIOLOGICAL MARKERS; BIOMETRY; CELL COUNT; CHLORAMBUCIL; CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; ENDPOINT DETERMINATION; FRANCE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES; LIKELIHOOD FUNCTIONS; LINEAR MODELS; LONGITUDINAL STUDIES; MULTIVARIATE ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38849124853     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3142     Document Type: Conference Paper

References (18)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69:89-95.
2. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine 2006; 25(2):183-203.
3. Molenberghs G, Burzykowski T, Alonso A, Buyse M. A perspective on surrogate endpoints in controlled clinical trials. Statistical Methods in Medical Research 2004; 13:177-206.
4. Burzykowski T, Molenberghs G, Buyse M. The Evaluation of Surrogate Endpoints. Springer: New York, 2005.
5. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Statistics in Medicine 1997; 16:1515-1527.
6. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statistics in Medicine 2007; 26(11):2389-2430.
7. French Cooperative Group on Chronic Lymphocytic Leukaemia. Effectiveness of CHOP regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; 1(8494):1346-1349.
8. French Cooperative Group on Chronic Lymphocytic Leukaemia. Leukemia therapeutic results from the trials managed by the French cooperative group on chronic lymphocytic leukemia. Leukemia Lymphoma 1991; 5(Suppl):83-88.
9. Therneau TM, Grambsch PM. Multiple events per subject. In Modeling Survival Data: Extending the Cox Model, Therneau TM, Grambsch PM (eds). Springer: New York, 2000; 169-229.
10. Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika 1981; 68:373-379.
11. Slasor P, Laird N. Joint models for efficient estimation in proportional hazards regression models. Statistics in Medicine 2003; 22(13):2137-2148.
12. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics 2000; 1(4):465-480.
13. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985; 41(2):361-372.
14. Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician 2004; 58:16-24.
15. Kay R. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 1986; 42(4):855-865.
16. Taylor JM, Wang Y. Surrogate markers and joint models for longitudinal and survival data. Controlled Clinical Trials 2002; 23(6):626-634.
17. Song X, Davidian M, Tsiatis A. An estimator for the proportional hazards model with multiple longitudinal covariates measured with error. Biostatistics 2002; 3(4):511-528.
18. Song X, Davidian M, Tsiatis A. A semiparametric likelihood approach to joint modeling of longitudinal and time-to-event data. Biometrics 2002; 58(4):742-753.